Salut Monràs

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy.

🧬🩸 Salud Personalizada para personas saludables 💯 Mejora tu estado de salud con tu programa de cambio de hábitos 100% individualizado, 100% adaptado a ti y a lo que te hace único 📝Te proporcionamos recomendaciones rigurosas y fácilmente accionables curadas por nuestro equipo de profesionales sanitarios, con las que conseguirás resultados reales y maximizarás tu estado de salud

🧬🩸 Salud Personalizada para personas saludables 💯 Mejora tu estado de salud con tu programa de cambio de hábitos 100% individualizado, 100% adaptado a ti y a lo que te hace único 📝Te proporcionamos recomendaciones rigurosas y fácilmente accionables curadas por nuestro equipo de profesionales sanitarios, con las que conseguirás resultados reales y maximizarás tu estado de salud

BOO BOO The brand es una concept store que busca hacerse un hueco entre los adeptos a un estilo de vida actual y de tendencia. Una marca de espíritu mediterráneo a caballo entre lo rústico y lo contemporáneo. La selección de sus piezas y diseños están pensados para ser atemporales y adaptables a todas las estaciones del año y hogares posibles. BOO BOO The brand se caracteriza por la búsqueda de lo nuevo mezclando las últimas tendencias con el trabajo artesanal y delicado con una filosofía inspirada en los detalles, la sencillez y la delicadeza de las cosas bien hechas.

Nemuru is a financial infrastructure platform empowering businesses to offer multi-lender and alternative payment solutions seamlessly. We provide end-to-end capabilities that enable companies to orchestrate financing strategies, unlock new revenue streams, and accelerate growth. Our mission is to democratize access to credit—making it faster, easier and available anytime, anywhere. Through our platform and APIs, partners can integrate branded financing experiences quickly and efficiently—delivering embedded credit solutions with maximum flexibility. Nemuru operates across 5+ European markets and Mexico, with continuous expansion underway. Learn more at www.nemuru.com or reach out at hola@nemuru.com.

Nemuru is a financial infrastructure platform empowering businesses to offer multi-lender and alternative payment solutions seamlessly. We provide end-to-end capabilities that enable companies to orchestrate financing strategies, unlock new revenue streams, and accelerate growth. Our mission is to democratize access to credit—making it faster, easier and available anytime, anywhere. Through our platform and APIs, partners can integrate branded financing experiences quickly and efficiently—delivering embedded credit solutions with maximum flexibility. Nemuru operates across 5+ European markets and Mexico, with continuous expansion underway. Learn more at www.nemuru.com or reach out at hola@nemuru.com.

Bionure is a clinical-stage biotech company developing therapies for the treatment of neurodegenerative diseases for which no treatment options are nowadays available. We focus in two conditions in which patients suffer from vision impairment and blindness, paralysis and even death: acute optic neuritis and neuromyelitis optica. Our lead candidate ACT01 (BN201) is a small molecule, new chemical entity, first-in-class drug that has been shown to promote neuroprotection and remyelination in several animal models of damage. BN201 has been granted orphan designation for acute optic neuritis in Europe and the US and the product is now in clinical Phase 2 (study ACUITY) in France. With patients in mind, we have built an extraordinary, committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.

Atomian develops cognitive computing (Artificial Intelligence) technology that saves +95% of the time in reading, understanding and extracting key knowledge from any document, with +99% accuracy. The differential value that Atomian's technology provides is that it understands texts like a person, that is, it understands highly composed, complex text, and the context of the document itself. On top, Atomian understands the Spanish, English and Catalan languages natively. Contact us for a demo at info@atomian.com

Atomian develops cognitive computing (Artificial Intelligence) technology that saves +95% of the time in reading, understanding and extracting key knowledge from any document, with +99% accuracy. The differential value that Atomian's technology provides is that it understands texts like a person, that is, it understands highly composed, complex text, and the context of the document itself. On top, Atomian understands the Spanish, English and Catalan languages natively. Contact us for a demo at info@atomian.com

Bionure is a clinical-stage biotech company developing therapies for the treatment of neurodegenerative diseases for which no treatment options are nowadays available. We focus in two conditions in which patients suffer from vision impairment and blindness, paralysis and even death: acute optic neuritis and neuromyelitis optica. Our lead candidate ACT01 (BN201) is a small molecule, new chemical entity, first-in-class drug that has been shown to promote neuroprotection and remyelination in several animal models of damage. BN201 has been granted orphan designation for acute optic neuritis in Europe and the US and the product is now in clinical Phase 2 (study ACUITY) in France. With patients in mind, we have built an extraordinary, committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.

Bionure is a clinical-stage biotech company developing therapies for the treatment of neurodegenerative diseases for which no treatment options are nowadays available. We focus in two conditions in which patients suffer from vision impairment and blindness, paralysis and even death: acute optic neuritis and neuromyelitis optica. Our lead candidate ACT01 (BN201) is a small molecule, new chemical entity, first-in-class drug that has been shown to promote neuroprotection and remyelination in several animal models of damage. BN201 has been granted orphan designation for acute optic neuritis in Europe and the US and the product is now in clinical Phase 2 (study ACUITY) in France. With patients in mind, we have built an extraordinary, committed team of experts in neuro-ophthalmology and neuro-inflammation, passionate about bringing meaningful therapies to society with the aim of changing the life of thousands of people.

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy.

🧬🩸 Salud Personalizada para personas saludables 💯 Mejora tu estado de salud con tu programa de cambio de hábitos 100% individualizado, 100% adaptado a ti y a lo que te hace único 📝Te proporcionamos recomendaciones rigurosas y fácilmente accionables curadas por nuestro equipo de profesionales sanitarios, con las que conseguirás resultados reales y maximizarás tu estado de salud

🧬🩸 Salud Personalizada para personas saludables 💯 Mejora tu estado de salud con tu programa de cambio de hábitos 100% individualizado, 100% adaptado a ti y a lo que te hace único 📝Te proporcionamos recomendaciones rigurosas y fácilmente accionables curadas por nuestro equipo de profesionales sanitarios, con las que conseguirás resultados reales y maximizarás tu estado de salud

BOO BOO The brand es una concept store que busca hacerse un hueco entre los adeptos a un estilo de vida actual y de tendencia. Una marca de espíritu mediterráneo a caballo entre lo rústico y lo contemporáneo. La selección de sus piezas y diseños están pensados para ser atemporales y adaptables a todas las estaciones del año y hogares posibles. BOO BOO The brand se caracteriza por la búsqueda de lo nuevo mezclando las últimas tendencias con el trabajo artesanal y delicado con una filosofía inspirada en los detalles, la sencillez y la delicadeza de las cosas bien hechas.

En Mother Media Group estamos especializados en comunicación digital, influencer marketing, consultoría digital implementada en plataformas sociales y producción de contenido audiovisual. Formamos parte del ecosistema digital, creciendo día a día de la mano de marcas e influencers con los que generamos valor a través de ideas únicas y disruptivas.